O051. Chronic migraine and onabotulinumtoxinA: a prospective study on patients treated at the Headache Centre of the Padua University and analysis of possible predictors of responsivity

Materials and methods By compiling a headache diary, efficacy parameters (mean reduction of headache days and hours) were evaluated at 90 days after the first cycle. We analyzed also: 30% and 50% response rates and the percent of firsttime responders to II cycle; association with headache related symptoms and comorbidities (depression/anxiety disorders, hypertension, sleep disturbances, caffeine intake, BMI >30).